Blue Earth Therapeutics today announced further promising developments for its radiohybrid lutetium labelled, PSMA targeted, ...

Results from the company’s Phase I/II trial showed the injectable therapy to have an effective half-life of 91.4 hours.

As federal and state governments look for ways to save money, there is one project Missouri sees fit for extra investments: ...

Lutetium-177 (Lu-177) Market is Segmented by Type (Non-carrier-added, Carrier-added), by Application (Nuclear Therapy, Others). The Lutetium-177 market is poised for significant expansion as ...

Prostate cancer poses significant challenges for many patients. Radioligand therapies have offered hope by targeting cancer cells with precision. While Lutetium-177 therapy has been effective for many ...

ITM Isotope Technologies Munich SE is gearing up to enter the US market with its radiopharmaceutical therapy, ITM-11 ...

The PSMA targeting ligand in Pluvicto™, is chemically attached to a therapeutic radioactive atom called Lutetium-177 (177Lu), which releases an energetic beta particle to precisely deliver cell ...

Cancer-control outcomes of metastatic castration resistant prostate cancer patients with BRCA-gene or tumor suppressor mutations undergoing 177-lutetium PSMA radioligand therapy.

(Novartis) welcomes the Government of Alberta's decision to publicly reimburse Pluvicto� (lutetium (177Lu) vipivotide tetraxetan injection) for eligible patients with prostate-specific membrane ...

1,2 The Phase 1 data shows that Lutetium (177 Lu) rhPSMA-10.1 Injection has high ratios for absorbed radiation dose to tumours vs. dose to healthy tissues, with a measured mean tumour to salivary ...